← Oncology Approval Tracker

FDA DECISION ·

Trodelvy

sacituzumab govitecan-hziy · Gilead Sciences

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line monotherapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1 or PD-L1 inhibitor-based therapy.

LAMPGEN ANALYSIS

Why it matters

ASCENT-03 brings a TROP2-directed antibody-drug conjugate into the first-line setting for patients who cannot receive checkpoint inhibitor-based therapy.

What research teams should watch

Document why the patient is ineligible for checkpoint therapy, then track baseline status, neutropenia and diarrhea. Keep this population separate from the PD-L1-selected combination.

PRIMARY RECORDS

Sources